EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent - Update 2013

European Urology

Volumn 65, Issue 1, 2014, Pages 124-137

  Heidenreich, Axel ^a   Bastian, Patrick J ^b   Bellmunt, Joaquim ^c   Bolla, Michel ^d   Joniau, Steven ^e   Van Der Kwast, Theodor ^f   Mason, Malcolm ^g   Matveev, Vsevolod ^h   Wiegel, Thomas ⁱ   Zattoni, F ^j   Mottet, Nicolas ^k  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Klinikum Golzheim   (Germany)

^c HOSPITAL DEL MAR   (Spain)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g VELINDRE CANCER CENTRE   (United Kingdom)

^h INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^k Clinique Mutaliste de la Loire   (France)

more..

Author keywords

Androgen deprivation; Diagnosis; EAU guidelines; Follow up; Prostate cancer; Radiation therapy; Radical prostatectomy; Review; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC PROCEDURE; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; ION THERAPY; LOCAL ANESTHESIA; LOCAL THERAPY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTON RADIATION; TRANSRECTAL ULTRASONOGRAPHY; WATCHFUL WAITING; EARLY DIAGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84888815889     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.09.046     Document Type: Article

References (113)

1. A. Heidenreich, J. Bellmunt, M. Bolla European Association of Urology EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
2. Agency for Healthcare Research and Quality (formerly known as the Agency for Health Care Policy and Research) Web site. http://www.ahrq.gov/.
3. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
4. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe 2008 Eur J Cancer 46 2010 765 781
5. O. Bratt Hereditary prostate cancer: clinical aspects J Urol 168 2002 906 913
6. M.F. Leitzmann, and S. Rohrmann Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates Clin Epidemiol 4 2012 1 11
7. E.A. Klein, I.M. Thompson Jr., and C.M. Tangen Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 306 2011 1549 1556
8. L.H. Sobin, M. Gospodariwicz, and C. Wittekind TNM classification of malignant tumors ed. 7. 2009 Wiley-Blackwell Hoboken, NJ p. 243-8
9. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
10. D. Ilic, D. O'Connor, S. Green, and T. Wilt Screening for prostate cancer: a Cochrane systematic review Cancer Causes Control 18 2007 279 285
11. G.L. Andriole, E.D. Crawford, R.L. Grubb III PLCO Project Team Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
12. F.H. Schröder, J. Hugosson, M.J. Roobol ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
13. F.H. Schröder, J. Hugosson, Roobol ERSPC Investigators Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
14. A. Heidenreich, P.A. Abrahamsson, and W. Artibani Early detection of prostate cancer: European Association of Urology recommendation Eur Urol 64 2013 347 354
15. H.B. Carter, A.E. Kettermann, L. Ferrucci, P. Landis, B.J. Trock, and E.J. Metter Prostate specific antigen testing among the elderly; when to stop [abstract 1751]? J Urol 174 Suppl 1 2008 600
16. A.J. Vickers, D. Ulmert, and D.D. Sjoberg Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study BMJ 346 2013 f2023
17. G.F. Carvalhal, D.S. Smith, D.E. Mager, C. Ramos, and W.J. Catalona Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less J Urol 161 1999 835 839
18. S. Loeb, and W.J. Catalona What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? Nat Clin Pract Urol 6 2009 68 69
19. C. Stephan, T. Köpke, and A. Semjonow Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med 47 2009 1325 1331
20. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per millilitre N Engl J Med 350 2004 2239 2246
21. Y. Kobori, Y. Kitagawa, A. Mizokami, K. Komatsu, and M. Namiki Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0 ng/ml as a criterion Int J Clin Oncol 13 2008 229 232
22. M.F. O'Brien, A.M. Cronin, and P.A. Fearn Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy J Clin Oncol 27 2009 3591 3597
23. A.J. Vickers, C. Savage, M.F. O'Brien, and H. Lilja Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer J Clin Oncol 27 2009 398 403
24. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1589
25. M. Remzi, A. Haese, and H. van Poppel Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106 2010 1138 1142
26. G. Ploussard, A. Haese, and H. van Poppel The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 106 2010 1143 1147
27. R. Hara, Y. Jo, and T. Fujii Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy Urology 71 2008 191 195
28. A. Takenaka, R. Hara, and T. Ishimura A prospective randomized comparison of diagnostic efficiency between transperineal and transrectal 12-core prostate biopsy Prostate Cancer Prostatic Dis 11 2008 134 138
29. K. Eichler, S. Hempel, J. Wilby, L. Myers, L.M. Bachmann, and J. Kleijnen Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review J Urol 175 2006 1605 1612
30. M. Aron, T.P. Rajeev, and N.P. Gupta Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study BJU Int 85 2000 682 685
31. O. Cuevas, J. Oteo, E. Lázaro Spanish EARS-Net Study Group Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid J Antimicrob Chemother 66 2011 664 669
32. S. Loeb, H.B. Carter, and S.I. Berndt Complications after prostate biopsy: data from SEER-Medicare J Urol 186 2011 1830 1834
33. I. Adamakis, D. Mitropoulos, K. Haritopoulos, C. Alamanis, K. Stravodimos, and A. Giannopoulos Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream World J Urol 22 2004 281 284
34. J.L. Merrimen, G. Jones, D. Walker, C.S. Leung, L.R. Kapusta, and J.R. Srigley Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma J Urol 182 2009 485 490
35. N. Arumainayagam, H.U. Ahmed, and C.M. Moore Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard Radiology 268 2013 761 769
36. Sonn GA, Chang E, Natarajan S, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. In press. http://dx.doi.org/10. 1016/j.eururo.2013.03.025.
37. T.H. Van der Kwast, C. Lopes, C. Santonja Members of the Pathology Committee of the European Randomised Study of Screening for Prostate Cancer Guidelines for processing and reporting of prostatic needle biopsies J Clin Pathol 56 2003 336 340
38. S.W. Fine, M.B. Amin, and D.M. Berney A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens Eur Urol 62 2012 20 39
39. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, L.L. Egevad ISUP Grading Committee The 2005 International Society of Urologic Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma Am J Surg Pathol 29 2005 1228 1242
40. L. Wang, H. Hricak, M.W. Kattan, H.N. Chen, K. Kuroiwa, and H.F. Eisemberg Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MRI to the Kattan nomogram Radiology 242 2007 182 188
41. A.M. Hoivels, R.A.M. Heesakkers, and E.M. Adang The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis Clin Radiol 63 2008 387 395
42. D.B. Husarik, R. Miralbell, and M. Dubs Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 2008 253 263
43. R. Schiavina, V. Scattoni, and P. Castellucci (11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms Eur Urol 54 2008 392 401
44. A. Heidenreich, Z. Varga, and R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis J Urol 167 2002 1681 1686
45. A. Briganti, N. Passoni, and M. Ferrari When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool Eur Urol 57 2010 551 558
46. G.W. Chodak, R.A. Thisted, and G.S. Gerber Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242 248
47. P.C. Albertsen, J.A. Hanley, D.F. Gleason, and M.J. Barry Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975 980
48. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
49. L. Klotz Active surveillance for prostate cancer: a review Curr Urol Rep 11 2010 165 171
50. Y. Krakowsky, A. Loblaw, and L. Klotz Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics J Urol 184 2010 131 135
51. M. Al Otaibi, P. Ross, and N. Fahmy Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance Cancer 113 2008 286 292
52. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810 2816
53. M. Bul, X. Zhu, and R. Valdagni Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597 603
54. L. Holmberg, A. Bill-Axelson, and G. Steineck Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting J Natl Cancer Inst Monogr 2012 2012 230 233
55. T.J. Wilt, M.K. Brawer, K.M. Jones Prostate Cancer Intervention Versus Observation Trial (PIVOT) Study Group Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
56. A. Vickers, C. Bennette, and G. Steineck Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial Eur Urol 62 2012 204 209
57. G. Novara, V. Ficarra, and R.C. Rosen Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy Eur Urol 62 2012 431 452
58. V. Ficarra, G. Novara, and R.C. Rosen Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy Eur Urol 62 2012 405 417
59. G. Novara, V. Ficarra, and S. Mocellin Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy Eur Urol 62 2012 382 404
60. V. Ficarra, G. Novara, and T.E. Ahlering Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy Eur Urol 62 2012 418 430
61. A. Heidenreich, D. Pfister, D. Thüer, and B. Brehmer Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy BJU Int 107 2011 220 225
62. A. Briganti, A. Larcher, and F. Abdollah Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores Eur Urol 61 2012 480 487
63. S. Joniau, L. Van den Bergh, and E. Lerut Mapping of pelvic lymph node metastases in prostate cancer Eur Urol 63 2013 450 458
64. G. Bauman, R.B. Rumble, J. Chen, A. Loblaw, and P. Warde Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of prostate cancer Clin Oncol (R Coll Radiol) 24 2012 461 473
65. P. Kupelian, D. Kuban, and H. Thames Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995 Int J Radiat Oncol Biol Phys 61 2005 415 419
66. D. Ash, A. Flynn, J. Batterman, T. de Reijke, P. Lavagnini, L. Blank ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer Radiother Oncol 57 2000 315 321
67. S. Voulgaris, J.P. Nobes, R.W. Laing, and S.E. Langley State-of-the-art: prostate LDR brachytherapy Prostate Cancer Prostatic Dis 11 2008 237 240
68. W.J. Morris, M. Keyes, and I. Spadinger Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer Cancer 119 2013 1537 1546
69. G.K. Hunter, C.A. Reddy, and E.A. Klein Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer Prostate Cancer 2012 2012 853487 10.1155/2012/853487
70. O. Yossepowitch, S.E. Eggener, and F.J. Bianco Jr. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods J Urol 178 2007 493 499 discussion 499
71. J.F. Ward, J.M. Slezak, M.L. Blute, E.J. Bergstralh, and H. Zincke Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome BJU Int 95 2005 751 756
72. P.M. Pierorazio, T.J. Guzzo, and M. Han Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen Urology 76 2010 715 721
73. C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, and H. Van Poppel Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience Eur Urol 51 2007 121 129 discussion 128-9
74. H. Van Poppel, and S. Joniau An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer Eur Urol 53 2008 253 259
75. S. Loeb, N.D. Smith, K.A. Roehl, and W.J. Catalona Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer Urology 69 2007 1170 1175
76. T. Schlomm, P. Tennstedt, and C. Huxhold Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients Eur Urol 62 2012 333 340
77. M. Spahn, S. Joniau, and P. Gontero Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients Eur Urol 58 2010 1 7
78. P. Gontero, M. Spahn, and B. Tombal Is there a prostate-specific antigen upper limit for radical prostatectomy? BJU Int 108 2011 1093 1100
79. R. Ghavamian, E.J. Bergstralh, and M.L. Blute Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison J Urol 161 1999 1223 1227
80. J. Engel, P.J. Bastian, and H. Baur Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer Eur Urol 57 2010 754 761
81. A. Briganti, J.R. Karnes, and L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer: a new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270
82. E.M. Messing, J. Manola, J. Yao Eastern Cooperative Oncology Group Study EST 3886 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479
83. D.G. McLeod, P. Iversen, W.A. See, T. Morris, J. Armstrong, M.P. Wirth Casodex Early Prostate Cancer Trialists' Group Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
84. Y.N. Wong, S. Freedland, B. Egleston, G. Hudes, J.S. Schwartz, and K. Armstrong Role of androgen deprivation therapy for node-positive prostate cancer J Clin Oncol 27 2009 100 105
85. A. Briganti, R.J. Karnes, and L.F. Da Pozzo Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis Eur Urol 59 2011 832 840
86. M. Bolla, H. van Poppel, L. Collette European Organization for Research and Treatment of Cancer Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
87. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
88. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
89. K. Zakeri, B.S. Rose, S. Gulaya, A.V. D'Amico, and L.K. Mell Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794 Contemp Clin Trials 34 2013 74 79
90. M. Bolla, H. van Poppel, B. Tombal European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
91. A.J. Stephenson, P.T. Scardino, and M.W. Kattan Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041
92. A. Siegmann, D. Bottke, and J. Faehndrich Salvage radiotherapy after prostatectomy: What is the best time to treat? Radiother Oncol 103 2012 239 243
93. A. Briganti, T. Wiegel, and S. Joniau Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis Eur Urol 62 2012 472 487
94. D. Krauss, L. Kestin, and H. Ye A lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer Int J Radiat Oncol Biol Phys 80 2011 1064 1071
95. P.A. Kupelian, J. Ciezki, and C.A. Reddy Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer Int J Radiat Oncol Biol Phys 71 2008 16 22
96. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
97. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
98. Nabid A, Carrier N, Martin AG, et al. High risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study [abstract 3]. Presented at: ASCO Genitourinary Cancers Symposium; February 14-16, 2013; Orlando, FL, USA.
99. M. Bolla, T.M. de Reijke, G. Van Tienhoven EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
100. G.E. Hanks, T.F. Pajak, A. Porter Radiation Therapy Oncology Group Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
101. A. Widmark, O. Klepp, A. Solberg Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
102. P. Warde, M. Mason, K. Ding NCIC CTG PR.3/MRC UK PR07 Investigators Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2012 2104 2111
103. N. Mottet, M. Peneau, J.J. Mazeron, V. Molinie, and P. Richaud Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial Eur Urol 62 2012 213 219
104. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
105. C.A. Lawton, M. DeSilvio, and M. Roach III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
106. S.A. Leibel, Z. Fuks, and M.J. Zelefsky The effects of local and regional treatments on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement Int J Radiat Oncol Biol Phys 28 1994 7 16
107. S.O. Asbell, J.M. Krall, and M.V. Pilepich Elective irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77 06 Int J Radiat Oncol Biol Phys 15 1988 1307 1316
108. J.A. Efstathiou, P.J. Gray, and A.L. Zietman Proton beam therapy and localised prostate cancer: current status and controversies Br J Cancer 108 2013 1225 1230
109. J.A. Talcott, C. Rossi, and W.U. Shipley Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer JAMA 303 2010 1046 1053
110. R.J. Babaian, B. Donnelly, and D. Bahn Best practice statement on cryosurgery for the treatment of localized prostate cancer J Urol 180 2008 1993 2004
111. S. Crouzet, X. Rebillard, and D. Chevallier Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients Eur Urol 58 2010 559 566
112. M. Warmuth, T. Johansson, and P. Mad Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer Eur Urol 58 2010 803 815
113. B.J. Donnelly, J.C. Saliken, and P.M. Brasher A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer Cancer 116 2010 323 330